Canopy Health Innovations ("Canopy Health" or "CHI"), the partly-owned biopharmaceutical research and development affiliate of Canopy Growth Corporation (TSX: WEED) ("Canopy Growth"), today announced that it has, alone or with its subsidiary Canopy Animal Health or through its joint-venture Beckley Canopy Therapeutics, filed eight provisional US patents pertaining to the delivery and application of cannabis and cannabinoid-based therapeutics in certain indications. Specifically, the eight patent applications relate to the following:

• Fibromyalgia
• Amyotrophic Lateral Sclerosis (also known as ALS, Lou Gehrig's disease)
• Anxiety and its various sub-groups (in humans and animals, in conjunction with Canopy Animal Health)
• Cognitive enhancement (in humans and animals, in conjunction with Canopy Animal Health)
• Pain and various sub-groups (in humans and animals, in conjunction with Canopy Animal Health)
• Opioid sparing, pain management, and addiction (through Beckley Canopy Therapeutics)
• Addiction and smoking cessation (through Beckley Canopy Therapeutics)
• A platform and method for delivery of cannabis-based compositions

In addition to updated applications relating to earlier Insomnia patent applications, this brings the total number of US provisional patent filings (including Canopy Animal Health and Beckley Canopy Therapeutics) to thirty-nine.

These filings are part of a concerted plan to bring to patients and healthcare providers innovative medicines and health products targeting disease areas with substantial medical needs. As part of this plan, Canopy Health and its affiliates are collaborating with respected world-class academic researchers and clinicians, and working with leading research organizations and regulators in jurisdictions of interest to develop and register these breakthrough products.

"As global medical markets emerge the trend among regulators favours highly regulated and highly repeatable medical cannabis options," said Bruce Linton, Chairman & CEO, Canopy Growth. "Through Canopy Health's work we are bulding a body of knowledge around cannabinoid medicine that will lead to its inclusion in mainstream healthcare for the benefit of patients."

Canopy Health and its affiliates continue their practice of filing provisional patents in the United States, which is common in the field of intellectual property generation and protection. Patents are first filed in the United States to create a priority date and allow for future filings in other selected jurisdictions, including Canada.

Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most common "first to file" jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids.

Here's to Future Growth.